These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27288063)

  • 41. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
    Aygören-Pürsün E; Scharrer I
    Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Turoctocog alfa for the treatment of hemophilia a.
    Vakil NH; Fujinami N; Martin-Stone S
    Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII.
    Konigs C; von Hentig N
    Drugs Today (Barc); 2009 Jul; 45(7):549-61. PubMed ID: 19834631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
    Kessler C; Oldenburg J; Ettingshausen CE; Tiede A; Khair K; Négrier C; Klamroth R
    Haemophilia; 2015 Jan; 21 Suppl 1():1-12. PubMed ID: 25472812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The first recombinant FVIII produced in human cells--an update on its clinical development programme.
    Valentino LA; Negrier C; Kohla G; Tiede A; Liesner R; Hart D; Knaub S
    Haemophilia; 2014 Jan; 20 Suppl 1():1-9. PubMed ID: 24330348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.
    Goudemand J; Rothschild C; Demiguel V; Vinciguerrat C; Lambert T; Chambost H; Borel-Derlon A; Claeyssens S; Laurian Y; Calvez T;
    Blood; 2006 Jan; 107(1):46-51. PubMed ID: 16166584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and characterization of recombinant ovine coagulation factor VIII.
    Zakas PM; Gangadharan B; Almeida-Porada G; Porada CD; Spencer HT; Doering CB
    PLoS One; 2012; 7(11):e49481. PubMed ID: 23152911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
    Ewenstein BM; Collins P; Tarantino MD; Negrier C; Blanchette V; Shapiro AD; Baker D; Spotts G; Sensel M; Yi SE; Gomperts ED
    Semin Hematol; 2004 Jan; 41(1 Suppl 2):1-16; discussion 16-8. PubMed ID: 15071785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII.
    Hillarp A; Holme PA; Wåland EP; Le MS; Henriksson CE; Tjønnfjord GE; Måseide RJ
    J Thromb Haemost; 2023 Oct; 21(10):2771-2775. PubMed ID: 37543216
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
    Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
    Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
    Di Minno G; Cerbone AM; Coppola A; Cimino E; Di Capua M; Pamparana F; Tufano A; Di Minno MN
    Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.